Current Edition

Upcoming Events

Advertisement

news

Blackstone-backed biotech launches with up to $300M for immune drug

Dive Brief: Uniquity Bio, a startup backed by Blackstone Life Sciences, is launching with a medicine ready for Phase 2 studies and as much as $300 million from t...
Continue Reading →
news

Bayer details layoffs as company shake-up continues

German pharmaceutical company Bayer eliminated 1,500 roles during the first three months of the year as part of a company makeover CEO Bill Anderson promised last ye...
Continue Reading →
news

Takeda targets ‘efficiency’ in restructuring, pipeline cuts

Dive Brief: Takeda plans to simplify how its workforce is organized, cut spending and slim down its drug pipeline in a restructuring aimed at improving its profi...
Continue Reading →
news

Ajax, aiming for a better JAK drug, raises $95M to begin first tests

Medicines called JAK inhibitors are well known in the pharmaceutical industry. Several are approved to treat inflammatory disease conditions or cancer, and regularly...
Continue Reading →
news

London Biotechnology Show Opens Its Doors Tomorrow at Olympia West

The most-awaited London Biotechnology Show will finally open its doors tomorrow at Olympia West, London, UK. #LBS24 is a 2 day conference & exhibition that will ...
Continue Reading →
news

Cytomos offers sneak preview of flagship technology at the London Biotechnology Show 2024 

1st May 2024: TechBio company Cytomos (www.cytomos.com) will be giving visitors to this year’s London Biotechnology Show a sneak preview of Celledo...
Continue Reading →
news

Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study

Cerevel Therapeutics, a biotechnology company in the midst of being acquired by AbbVie, on Thursday said a Parkinson’s disease treatment it’s developing succeeded in...
Continue Reading →
news

Roche wins FDA OK for Alecensa in early lung cancer

The Food and Drug Administration has made a medicine from Roche the first specifically available for early treatment of lung tumors driven by a well-known cancer gen...
Continue Reading →
news

Vertex begins bid for US approval of non-opioid painkiller

Vertex Pharmaceuticals is vying for approval of an experimental and closely watched painkiller that could become an alternative to addictive opioids like Vicodin. ...
Continue Reading →
news

Alvotech deal could heighten biosimilar pressure on Humira

Dive Brief: Alvotech and U.S. commercial partner Teva have signed a “long-term agreement” with an unspecified company to boost access to their biosimilar version...
Continue Reading →